SER 101
Alternative Names: RO1160367; SER101Latest Information Update: 16 Jul 2016
At a glance
- Originator Roche
- Class
- Mechanism of Action Serotonin 4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Heart-failure in Europe
- 13 Dec 2010 Roche grants Serodus exclusive worldwide development, manufacturing and commercialisation rights for its serotonin 4 receptor antagonist for the treatment of heart failure
- 13 Dec 2010 Phase-I clinical trials in Congestive heart failure in Europe (unspecified route)